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The authors have advised there is an error with [Figure 2](#F0002a){ref-type="fig"} on page 3170. The figure parts C-H do not match the description in the figure caption or figure citations throughout the text.

The correct [Figure 2](#F0002a){ref-type="fig"} is shown below. The authors apologize for this error. Figure 2Continued. Figure 2Subgroup analysis of OS and PFS. (**A**) Subgroup with AFP \>400μg/L, whether HTN can be a predictor of OS; (**B**) subgroup with AFP \>400μg/L, whether HTN can be a predictor of PFS; (**A, B**) In patients with AFP ≤400μg, drug-related HTN can be used as a predictor of OS (p=0.006) and PFS (p=0.021). In patients with AFP \>400μg, drug-related HTN cannot be used as a predictor of OS (p=0.081), but can be used as a predictor of PFS (p=0.007). (**C**) Subgroup with Child-Pugh Score, whether HTN can be a predictor of OS; (**D**) subgroup with Child-Pugh Score, whether HTN can be a predictor of PFS; (**C, D**) in patients with Child-Pugh A, drug-related HTN can be used as a predictor of OS (p=0.003) and PFS (p=0.012). In patients with Child-Pugh B, drug-related HTN cannot be used as a predictor of OS (p=0.267), but can be used as a predictor of PFS (p=0.010). (**E**) Subgroup with macrovascular invasion, whether HTN can be a predictor of OS; (**F**) subgroup with macrovascular invasion, whether HTN can be a predictor of PFS; (**E, F**) in patients without macrovascular invasion, drug-related HTN can be used as a predictor of OS (p=0.024), but not as a predictor of PFS (p=0.072). In patients with macrovascular invasion, drug-related HTN can be used as a predictor of OS (p=0.021) and PFS (p=0.001). (**G**) Subgroup with extrahepatic spread, whether HTN can be a predictor of OS; (**H**) subgroup with extrahepatic spread, whether HTN can be a predictor of PFS. (**G, H**) In patients without extrahepatic metastases, drug-related HTN cannot be used as a predictor of OS (p=0.078), but can be used as a predictor of PFS (p=0.035). In patients with extrahepatic spread, drugrelated HTN can be used as a predictor of OS (p=0.005) and PFS (p=0.000).
